Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Obinutuzumab Benefit in Frontline Follicular Lymphoma Sustained With Longer Follow-Up
June 17th 2017At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.
BGB-3111 Plus Obinutuzumab Effective in CLL and Follicular Lymphoma
June 17th 2017Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.
Dr. Nastoupil on Pembrolizumab Plus Rituximab in Relapsed Follicular Lymphoma
June 15th 2017Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.
Dr. Neelapu on Axi-Cel in the ZUMA-1 Trial for Refractory Aggressive Non-Hodgkin Lymphoma
June 15th 2017Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma.
Axicabtagene Ciloleucel NHL Data Presented as FDA Weighs Approval
June 15th 2017Patients with refractory aggressive non-Hodgkin lymphoma lacking curative treatment options demonstrated high response rates and durable responses plus a manageable safety profile following treatment with axicabtagene ciloleucel.
Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell Lymphoma
June 14th 2017Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).
ASCO Partners With FDA to Incorporate Real-World Evidence Into Drug Decisions
In recognition of the potential for real-world evidence to significantly improve the way patients with cancer are treated, CancerLinQ has formed new partnerships with the US government that are expected to coordinate the sharing of patient data and incorporate that information into the FDA regulatory process.
Osimertinib Improves Response in T790M+ NSCLC With CNS Metastases
Patients with T790M-positive non–small cell lung cancer had superior outcomes when treated with osimertinib (Tagrisso) for central nervous system metastases, according to phase III results presented at the 2017 ASCO Annual Meeting.
Dr. Ascierto on Triplet of Encorafenib, Binimetinib, and Ribociclib in Melanoma
June 9th 2017Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses findings from a phase Ib/II dose-escalation study evaluating the triple combination therapy with encorafenib, binimetinib, and ribociclib (Kisqali) in patients with BRAF V600-mutant solid tumors and melanoma.
Avelumab/Axitinib Combo Shows Promise in Frontline RCC
June 7th 2017Combining the PD-L1 inhibitor avelumab (Bavencio) with the VEGF inhibitor axitinib (Inlyta) as a frontline regimen induced a response rate of 58.2% in patients with advanced renal cell carcinoma, according to findings from the phase Ib JAVELIN Renal 100 trial presented at the 2017 ASCO Annual Meeting.
Dr. Garassino Discusses Promising Findings With Osimertinib for Patients With NSCLC and Brain Mets
June 6th 2017Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non–small cell lung cancer (NSCLC) who also harbor brain metastases.
Dr. West on Emerging Changes in the Field of EGFR-Mutant NSCLC
June 6th 2017H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses some potential emerging changes coming to the field of EGFR-mutant non–small cell lung cancer (NSCLC), including next-generation EGFR inhibitors such as osimertinib (Tagrisso) that is now being explored in the FLAURA trial as a frontline treatment for these patients.
